Carbon nanoparticles versus patent blue dye for detection of sentinel lymph node in patients with early breast cancer

被引:0
|
作者
Elsebaai, Mahmoud R. M. [1 ]
Shehab, Mohamed A. H. [1 ]
Hanafy, Dina M. [1 ]
Abd Al Moaty, Karim F. [1 ]
机构
[1] Ain Shams Univ, Fac Med, Gen Surg, 32 Mohamed Ibrahim, Cairo 11788, Egypt
来源
EGYPTIAN JOURNAL OF SURGERY | 2024年 / 43卷 / 02期
关键词
carbon nanoparticles; patent blue V dye; sentinel lymph nodes; QUALITY-OF-LIFE; BIOPSY; MULTICENTER; IDENTIFICATION; DISSECTION;
D O I
10.4103/ejs.ejs_311_23
中图分类号
R61 [外科手术学];
学科分类号
摘要
BackgroundSentinel lymph nodes biopsy (SLNB) has replaced axillary lymph node dissection (ALND) in a considerable percentage of patients with early-stage breast cancer which was a great advance in preventing many surgical complications and enhancing their health welfare. Although there are different sentinel lymph nodes (SLNs) tracers with different identification rates, there is no agreement about the idealistic method.AimThe study was designed to compare carbon nanoparticles and patent blue v dye regarding SLNs detection rate, number of SLNs, time of detection, metastatic SLNs, cost, and safety in patients with early breast cancer and clinically node-negative axilla.Patients and methodsA total of 40 patients with axillary lymph node-negative early-stage breast cancer patients were divided into two groups and subjected to carbon nanoparticles and patent blue V dye in group A and group B, respectively. Patients who were pregnant or lactating had node-positive axilla (N1-3) or metastatic breast cancer (M1) or had neoadjuvant chemotherapy were excluded.ResultsThe mean age was 48.3 +/- 9.5 and 47 +/- 8.9, while the mean BMI of 33.3 +/- 4.8 and 32.834 +/- 4.862, the SLN detection rates were 95% and 90% in groups A and B, respectively. A total of 128 sentinel lymph nodes (SLNs) were removed from patients in the two groups (65 with Carbon Nanoparticles and 63 with patent blue dye). The mean number of SLNs was 3.4 +/- 0.7 (range, 2-5) and 3.5 +/- 1.2 (range, 2-7), mean time of SLNs detection was 13.5 +/- 4.5 (range, 7-22) and 12.7 +/- 3.6 (range, 7-18 min) between group A and B, respectively.ConclusionThere is no significant difference between carbon nanoparticles and patent blue dye regarding axillary SLNs in early breast cancer regarding identification rate, number of SLNs, time of detection, metastatic SLNs, cost, and safety with slight preference to carbon nanoparticles regarding postoperative skin staining and Egyptian market availability.
引用
收藏
页码:485 / 492
页数:8
相关论文
共 50 条
  • [21] Blue dye is sufficient for sentinel lymph node biopsy in breast cancer
    Ang, C. H.
    Tan, M. Y.
    Teo, C.
    Seah, D. W.
    Chen, J. C.
    Chan, M. Y. P.
    Tan, E. Y.
    BRITISH JOURNAL OF SURGERY, 2014, 101 (04) : 383 - 389
  • [22] A new optical probe for the detection of the sentinel lymph node using patent blue V dye in breast cancer: A preliminary study
    Tellier, F.
    Poulet, P.
    Ghnassia, J. P.
    Wilt, M.
    Weitbruch, D.
    Rodier, J. F.
    MOLECULAR AND CLINICAL ONCOLOGY, 2013, 1 (01) : 143 - 147
  • [23] Sentinel lymph node identification by blue dye in patients with breast carcinoma
    Bakhtiar, Nighat
    Jaleel, Farhat
    Moosa, Foad Ali
    Qureshi, Naeem Akhtar
    Jawaid, Masood
    PAKISTAN JOURNAL OF MEDICAL SCIENCES, 2016, 32 (02) : 448 - 451
  • [24] Management of Axilla in Early Breast Cancer by Sentinel Lymph Node Biopsy Using Blue Dye
    Khanam, Andleeb
    Afzal, Hurriat
    Rafi, Yaseen
    Aslam, H.
    Khwaja, K.
    PAKISTAN JOURNAL OF MEDICAL & HEALTH SCIENCES, 2020, 14 (02): : 472 - 474
  • [25] Methylene blue dye versus combined dye-radioactive tracer technique for sentinel lymph node localisation in early breast cancer
    Varghese, P.
    Mostafa, A.
    Abdel-Rahman, A. T.
    Akberali, S.
    Gattuso, J.
    Canizales, A.
    Wells, C. A.
    Carpenter, R.
    EJSO, 2007, 33 (02): : 147 - 152
  • [26] Patent Blue Induced ADRs During Sentinel Lymph Node Detection in Tunisian Patients with Breast Cancer: Incidence and Characteristics
    Ouni, B.
    Mansour, K.
    Slim, R.
    Bannour, I.
    Bensalem, C.
    Fathallah, N.
    DRUG SAFETY, 2021, 44 (12) : 1458 - 1459
  • [27] Anaphylactic reaction to patent blue dye during sentinel lymph node biopsy in early-stage breast cancer - a case report
    Shinzato, Julia Yoriko
    Pereira Marcaccini, Ana Carolina
    de Assuncao Braga, Angelica de Ftima
    Ribeiro, Arneth Rodrigues
    Marco Rubio, Jose Eduardo
    Dias de Souza, Joao Paulo
    REVISTA BRASILEIRA DE GINECOLOGIA E OBSTETRICIA, 2006, 28 (12): : 728 - 732
  • [28] Is Blue Dye Indicated for Sentinel Lymph Node Biopsy in Breast Cancer Patients With a Positive Lymphoscintigram?
    Amy C. Degnim
    Kevin Oh
    Vincent M. Cimmino
    Kathleen M. Diehl
    Alfred E. Chang
    Lisa A. Newman
    Michael S. Sabel
    Annals of Surgical Oncology, 2005, 12 : 712 - 717
  • [29] Anaphylaxis after patent blue dye injection in breast surgery with sentinel lymph node biopsy
    Cardoso, Rita Goncalves
    Sepulveda, Daniela
    Ferreira, Sara Pontes
    Gomes, Ana Luisa
    Bezerra, Claudia
    ANESTHESIA AND ANALGESIA, 2021, 133 (3S_SUPPL): : 912 - 912
  • [30] Is blue dye indicated for sentinel lymph node biopsy in breast cancer patients with a positive lymphoscintigram?
    Degnim, AC
    Oh, K
    Cimmino, VM
    Diehl, KM
    Chang, AE
    Newman, LA
    Sabel, MS
    ANNALS OF SURGICAL ONCOLOGY, 2005, 12 (09) : 712 - 717